Five-Year Data Consolidate Cosentyx Benefits

 
• By Kevin Grogan

Cosentyx sales are growing at an impressive rate – up 37% in Q3 – and strong five-year safety and efficacy data in psoriatic arthritis and ankylosing spondylitis is likely to drive that growth even higher.

Building blocks
Cosentyx backed by five years of strong data in AS and PsA • Source: Shutterstock

More from Immunological

More from Therapy Areas